Immuno-Oncology beyond TILs: Unleashing TILCs
- PMID: 32289267
- DOI: 10.1016/j.ccell.2020.03.021
Immuno-Oncology beyond TILs: Unleashing TILCs
Abstract
Innate lymphoid cells (ILCs) are detected in multiple tumor types, but their contribution to tumor immunity remains unclear. Moral et al. show that a subset of tumor ILCs (TILCs) may participate in an organ-specific immune response and can be unleashed by PD-1 blockers to sustain tumor-specific T cell responses.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests O.D. and E.V. are employees of Innate Pharma.
Comment on
-
ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.Nature. 2020 Mar;579(7797):130-135. doi: 10.1038/s41586-020-2015-4. Epub 2020 Feb 19. Nature. 2020. PMID: 32076273 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical